Cargando…
Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541350/ https://www.ncbi.nlm.nih.gov/pubmed/37773550 http://dx.doi.org/10.1186/s13613-023-01194-x |
| _version_ | 1785113892417961984 |
|---|---|
| author | Chevret, Sylvie Bouadma, Lila Dupuis, Claire Burdet, Charles Timsit, Jean‑Francois |
| author_facet | Chevret, Sylvie Bouadma, Lila Dupuis, Claire Burdet, Charles Timsit, Jean‑Francois |
| author_sort | Chevret, Sylvie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10541350 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105413502023-10-01 Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial Chevret, Sylvie Bouadma, Lila Dupuis, Claire Burdet, Charles Timsit, Jean‑Francois Ann Intensive Care Correction Springer International Publishing 2023-09-29 /pmc/articles/PMC10541350/ /pubmed/37773550 http://dx.doi.org/10.1186/s13613-023-01194-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Chevret, Sylvie Bouadma, Lila Dupuis, Claire Burdet, Charles Timsit, Jean‑Francois Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial |
| title | Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial |
| title_full | Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial |
| title_fullStr | Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial |
| title_full_unstemmed | Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial |
| title_short | Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial |
| title_sort | correction: which severe covid-19 patients could benefit from high dose dexamethasone? a bayesian post-hoc reanalysis of the covidicus randomized clinical trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541350/ https://www.ncbi.nlm.nih.gov/pubmed/37773550 http://dx.doi.org/10.1186/s13613-023-01194-x |
| work_keys_str_mv | AT chevretsylvie correctionwhichseverecovid19patientscouldbenefitfromhighdosedexamethasoneabayesianposthocreanalysisofthecovidicusrandomizedclinicaltrial AT bouadmalila correctionwhichseverecovid19patientscouldbenefitfromhighdosedexamethasoneabayesianposthocreanalysisofthecovidicusrandomizedclinicaltrial AT dupuisclaire correctionwhichseverecovid19patientscouldbenefitfromhighdosedexamethasoneabayesianposthocreanalysisofthecovidicusrandomizedclinicaltrial AT burdetcharles correctionwhichseverecovid19patientscouldbenefitfromhighdosedexamethasoneabayesianposthocreanalysisofthecovidicusrandomizedclinicaltrial AT timsitjeanfrancois correctionwhichseverecovid19patientscouldbenefitfromhighdosedexamethasoneabayesianposthocreanalysisofthecovidicusrandomizedclinicaltrial AT correctionwhichseverecovid19patientscouldbenefitfromhighdosedexamethasoneabayesianposthocreanalysisofthecovidicusrandomizedclinicaltrial |